Renal Diseases Drug Development Pipeline Review: 2018 – Therapeutics Under

Click to copyhttps://apnews.com/bae813d4445e4fe0a62ac041b00fab5a

DUBLIN–(BUSINESS WIRE)–Jan 11, 2019–The “Renal Diseases Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

Renal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for renal diseases.

It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Chronic kidney disease is the slow loss of kidney function over time: There are 58 products in development for this indication.
Accumulation of extracellular matrix in the kidney: There are 49 products in development for this indication.
Polycystic kidney disease: There are 26 products in development for this indication.
End-stage kidney disease: There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.

Scope

Which companies are the most active within each pipeline?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in this disease area?

Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Profiled

AdAlta Ltd
Allena Pharmaceuticals Inc
apceth Biopharma GmbH
Arch Biopartners Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Corvidia Therapeutics Inc
DiaMedica Therapeutics Inc
DiscoveryBiomed Inc
DURECT Corp
Epigen Biosciences Inc
Galectin Therapeutics Inc
GenKyoTex SA
GNI Group Ltd
iBio Inc
IC-MedTech Inc
Ipsen SA
KBP BioSciences Co Ltd
Kidney Fibrosis
ManRos Therapeutics
Mironid Ltd
NovaTarg Therapeutics Inc
Novo Nordisk AS
OPKO Health Inc
Opsidio LLC
Otsuka Holdings Co Ltd
Pharmaxis Ltd
Q BioMed Inc
Redx Pharma PLC
Unity Biotechnology Inc
Vascular Biogenics Ltd
Vascular BioSciences
Vicore Pharma AB
and more…

For more information about this report visit https://www.researchandmarkets.com/research/jh93df/renal_diseases?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005123/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug
Discovery,Liver
and Kidney Disorders Drugs

KEYWORD: EUROPE NORTH AMERICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/11/2019 05:48 AM/DISC: 01/11/2019 05:48 AM

http://www.businesswire.com/news/home/20190111005123/en